- Seelos Therapeutics Inc's SEEL Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
- Under the orphan designation, Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees, and market exclusivity.
- Price Action: SEEL shares are up 2.9% at $3.17 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
